NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA
Executive Summary
FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
